Locations:

Research

22-CNR-3290544-CQD-Hero-prostate cancer 650×450

October 24, 2022/Cancer/Research

Study Reveals Gene Expression Patterns Associated With Aggressive Pathologic Features In Prostate Cancer

What is the role of molecular profiling in risk stratification?

22-CNR-3257217-CQD-Hero-Dr Geiger650x450

October 7, 2022/Cancer/Research

Cutaneous Squamous-cell Carcinoma Study Finds Complete Response to Immunotherapy in More than Half of Patients

Majority of patients achieve complete pathologic response after four-dose cemiplimab therapy

22-CNR-3235952-CQD-Hero-650×450 breast cancer

September 30, 2022/Cancer/Research

New Selective ER Modulator Shows Promising Clinical Activity in HR-positive Metastatic Breast Cancer with ESR1 Mutation After Progression

Impressive progression-free survival observed in phase 2 study

August 31, 2022/Cancer/Research

Investigational PET Imaging Agent Being Explored as a Predictive Biomarker For Response to Standard Chemotherapies

Pilot Study at Cleveland Clinic is Testing Feasibility and Biodistribution

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

August 22, 2022/Cancer/Research

Distinct PHTS-related Breast Cancer Genomic Characteristics Discovered

Findings support need for personalized disease management

22-CNR-3103108-CQD-Hero-650×450-LRI flip

August 9, 2022/Cancer/Research

Tumors with Specific Genetic Mutations Show Response to Immune Checkpoint Blockade Therapy

Pathogenic POLE/POLD1 mutations lead to improved response to immune checkpoint blockade therapy

21-CNR-2544358-CQD-Hero-650×450 DCIS biosignature

August 4, 2022/Cancer/Research

Biosignatures Optimize Adjuvant Radiation Therapy Decisions in Patients with DCIS

Tumor genomics offer clues for identifying high risk of relapse

22-CNR-3001718-CQD-Hero-650x450S-WOG 1318 Phase 2 Trial

July 28, 2022/Cancer/Research

Phase 2 Study Shows Promise for Treating Older Adults with Ph-Negative B-ALL

Blinatumomab followed by POMP maintenance shows effectiveness for newly diagnosed patients

22-CNR-3036012-CQD-Hero-650×450 colorectal cancer

July 26, 2022/Cancer/Research

Patients with MSI-High Colorectal Cancer Sought for Immunotherapy Trial

Study to test efficacy of immunotherapy with chemotherapy and radiation

July 22, 2022/Cancer/Research

New Paradigm Evolving for Treatment of Advanced Gliomas

Molecular targets may offer noncytotoxic treatment path

BackPage 9 of 26Next